Matt Hellmann, Senior Vice President of Early Oncology & Precision Medicine at AstraZeneca, shared a post on Linkedin:
“Combination therapies are at the heart of our AstraZeneca Oncology R&D strategy. These therapies require an innovative approach from the earliest stages of research all the way through to late-stage development and delivery.
Delivering these potentially transformative combinations and regimens, such as antibody drug conjugates paired with immuno-oncology therapies, is important and requires teamwork. The breadth and depth of our oncology portfolio is intentionally constructed to enable complementary combinations that can tackle the heterogeneity of cancer.
We’re constantly integrating insights from our teams and technologies across end-to-end development to guide our understanding of disease and how therapies could bring benefit to patients.
These unified approaches support our scientific discovery and ability to be patient-centered at every step. Read more in my article with Leora Horn about our strategy here.”